Source comparison
Melanotan-2 Results Timeline: Dose Comparison
The table below compares typical timelines and outcomes across three common MT2 dosing protocols observed in research literature. Timelines assume daily administration, fair-to-medium skin tone (Fitzpatrick II–III), and moderate UV co-exposure (2–3 sessions we
This comparison does not assign a generated winner or score.
- The table below compares typical timelines and outcomes across three common MT2 dosing protocols observed in research literature. Timelines assume daily administration, fair-to-medium skin tone (Fitzpatrick II–III), and moderate UV co-exposure (2–3 sessions weekly at sub-erythemal doses).
- 0.25mg daily
- Day 7–12
- 3–5 weeks
- 2–3× weekly
- Minimal; mild nausea in <10% of subjects
- Slowest onset but best-tolerated; suitable for cautious protocols or Fitzpatrick I subjects
- 0.5mg daily
- Day 5–8
- 2–3 weeks
- 2× weekly
- Moderate nausea (15–25%), facial flushing, mild appetite suppression
- Standard protocol; optimal balance of timeline and tolerability
- 1.0mg daily
- Day 3–6
- 10–14 days
- 1–2× weekly
- Nausea (30–40%), spontaneous erections (males), darkening of existing moles
- Fastest visible results but highest side effect incidence; not recommended for first-time use